Why the study?
Do angiotensin II receptor blockers (ARBs) prevent complications of hypertension compared to placebo or other antihypertensive drugs in patients with hypertension?
Do angiotensin II receptor blockers (ARBs) prevent complications of hypertension compared to placebo or other antihypertensive drugs in patients with hypertension?
Answers are grounded in this paper and cite their sources.
ARBs offer pleiotropic benefits beyond blood pressure lowering for preventing specific target organ damage and metabolic complications in hypertension, though not for myocardial infarction or heart failure.
Hypertension is a high-prevalence disease that may affect several organs. In recent years, data have accumulated indicating that angiotensin II receptor blockers (ARBs) may have a supplementary effect beyond lowering blood pressure. The aim of this review is to evaluate the impact of ARBs on the most important complications of hypertension--heart, cerebrovascular and renal diseases, and metabolic complications--based on the findings from large clinical hypertension trials. The results may indicate that ARBs have a superior effect compared with placebo or other antihypertensive drugs in order to prevent left ventricular hypertrophy, atrial fibrillation, stroke, renal disease and diabetes mellitus, while there appears to be no blood pressure-independent superior effect of ARBs regarding prevention of myocardial infarction or heart failure.
No takes yet. Share an insight, caveat, or question.
Flaa et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: